PROC in Practice: Navigating Biomarkers, Pipeline, and Patient Safety in Platinum-Resistant Ovarian Cancer

This activity is in collaboration with COA.

Program Description:

The treatment landscape for platinum-resistant ovarian cancer (PROC) is expanding, with new options targeting a range of molecular pathways. Biomarker testing is essential but not consistently implemented; results should be integrated with guidelines, prior therapy, clinical characteristics, and patient goals when sequencing treatment. Clinicians must also evaluate investigational agents and anticipate where they may fit within future treatment pathways. Pharmacists, including those in community oncology practice, support patient-centered treatment selection and safe therapy use through counseling, monitoring, early recognition of agent- and class-specific toxicities, and appropriate dose modification. This webinar prepares pharmacists to apply biomarkers and guidelines, evaluate emerging therapies, and proactively manage treatment-related toxicities.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: December 10, 2026
Expiration date: February 8, 2027
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply evolving biomarker testing results and National Comprehensive Cancer Network–aligned treatment pathways to select individualized therapy for patients with platinum-resistant ovarian cancer (PROC)
• Differentiate among investigational agents in the PROC pipeline based on molecular target, mechanism of action, and efficacy data
• Investigate patient-specific monitoring and dose-modification plans to prevent, recognize, and manage toxicities associated with newer PROC therapies

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-329-L01-P. The activity is available for CE credit through February 8, 2027.

Obtaining Credit

All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Erin Zacholski, PharmD, BCOP, has the following relevant financial relationship with an ineligible company to disclose:
Consultant: ImmunoGen (advisory board)

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Sarah Viruet; and Brianna Winters have no financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s), or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms